Paradigm Biopharmaceuticals Ltd has released a press release.
Paradigm Receives $7.4m R&D Tax Incentive Refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Paradigm Doses First UK Participant in Phase 3 Trial
- PAR Reports Successful Primary Endpoint in Phase 2 Trial
- Successful MPSVI Safety Review and PARA OA 008 Update
- Successful Completion of Entitlement Offer
- 2022 Annual Report and Appendix 4E
Later from Paradigm Biopharmaceuticals
- Paradigm CEO steps down & Appointment of MD
- PAR Receives Allowance for Key US Patent
- Phase 3 OA Trial to Proceed after Formal Safety Review
- iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
- iPPS shows 3-year equivalent durability in OA Canine Study
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals